Sept 2022: Maererano neongororo yakabudiswa mu Journal of Clinical Investigation, injiniya paYunivhesiti yeHouston (UH) angave akawana nzira yekuziva kuti ndevapi varwere ve lymphoma vangangopindura chimeric antigen receptor (CAR) T-cell therapy.
Physicians can expedite treatment and maybe save more lives if they are aware of which lymphoma patients react to CAR T-cell therapy. On the other hand, sharing light on people who react poorly and experience serious side effects can open up more possibilities for alternative treatments.
Vatsvagiri vakawana hukama hwakakosha pakati peT cell protein CD2 uye cancer receptor CD58 mukuferefeta kwavo.
In the tumours of lymphoma patients who benefit more from CAR T-cell kurapa, the CD2 ligand CD58 is expressed at higher levels, according to study author Navin Varadarajan, PhD, MD Anderson professor of chemical and biomolecular engineering.
AT cell's CD2 protein inosungwa neCD58. Kana CD58 ikamisa CD2, puroteni inoshanduka kuita mamorekuru anogona kudzima masero egomarara paanosangana.
According to certain recent studies, cancer can be treated by using the patient’s own biological system. One particular technique, called CAR T-cell kurapa, modifies T cells in the lab so that they will fight cancer cells once they have returned to the body. The consequences of this life-saving procedure could linger for ten years or longer.
Kuti aite ongororo yakadzama yekubatana pakati peCD58 neCD2, Varadarajan akabatana nechikwata chekutsvagisa kubva kuYunivhesiti yeTexas MD Anderson Cancer Center.
Varadarajan akabatana naSattva Neelapu (MD Anderson) kusvibisa mamota evarwere vasati varapwa neCAR T uye kuongorora sero kutaura vachishandisa TIMING (Timelapse Imaging Microscopy MuNanowell Grids) nzira yakagadziridzwa naVaradarajan murabhoritari yake. Iyi yepamusoro-soro tekinoroji-sero tekinoroji inogona kuongorora mafambiro anoita maseru, kuita, kuuraya, kurarama, uye kupindirana.
The scientists discovered that tumours expressing higher amounts of the cancer receptor CD58 responded better to CAR T-cell kurapa based on the hundreds of interactions they saw between T cells and tumour cells using TIMING.
Varadarajan stated in the news announcement, “We found that CD2 on T cells is related with directional migration. Death and serial killing are accelerated by the interaction between CD2 on T cells and CD58 on lymphoma masero.
Varadarajan irikuvavarira kushambadzira iyo TIMING maitiro. Akavamba bhizinesi reUH-based CellChorus. Varwere vanogona kuendesa CellChorus maseru avo ega ega; maseru aya anozoongororwa pachishandiswa bvunzo yeTIMING; sevhisi iyi haisati yasvika kune nyanzvi.
Mukuburitswa kwenhau, Varadarajan akati, "Isu tine rombo rakanaka kuva neTechnology Bridge senzvimbo yedu yekuisa incubator muHouston, padyo nenzvimbo yepamusoro yezvekurapa yenyika, ine mukana wakasiyana wenzvimbo dzemishonga dzinonetsa kudzokorora mune mamwe maguta mazhinji nyika.
